Research programme: NTCP inhibitors - Centre for Drug Design and Discovery
Latest Information Update: 02 May 2024
At a glance
- Originator Centre for Drug Design and Discovery
- Class Anti-inflammatories; Antivirals
- Mechanism of Action Sodium bile acid cotransporter expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Hepatitis B; Hepatitis D; Primary sclerosing cholangitis
Most Recent Events
- 24 Apr 2024 Research programme: NTCP inhibitors - Centre for Drug Design and Discovery is available for licensing as of 24 Apr 2024. https://www.cd3.be/
- 24 Apr 2024 Early research in Hepatitis B in Belgium (unspecified route) (Centre for Drug Design and Discovery pipeline, April 2024)
- 24 Apr 2024 Early research in Hepatitis D in Belgium (unspecified route) (Centre for Drug Design and Discovery pipeline, April 2024)